Los puntos clave no están disponibles para este artículo en este momento.
Abstract This retrospective observational study, building on prior research that demonstrated the efficacy of the Digital Twin (DT) Precision Treatment Program over shorter follow-up periods, aimed to examine glycemic control and reduced anti-diabetic medication use after one year in a DT commercial program. T2D patients enrolled had adequate hepatic and renal function and no recent cardiovascular events. DT intervention powered by artificial intelligence utilises precision nutrition, activity, sleep, and deep breathing exercises. Outcome measures included HbA1c change, medication reduction, anthropometrics, insulin markers, and CGM metrics. Of 1985 enrollees, 132 (6.6%) were lost to follow-up, leaving 1853 participants who completed one year. At one year, participants exhibited significant reductions in HbA1c mean change (SD) -1.8 (1.7)%, p<0.0001, with 1650 (89.0%) achieving HbA1c levels below 7%. At baseline, participants were taking mean anti-diabetic medications of 1.9 (1.4) which decreased to 0.5 (0.7) after one year change: -1.5 (1.3), p<0.0001. There were also significant decreases in weight -4.8 (6.0) kg, p<0.0001, improvements in insulin resistance as measured by HOMA2-IR -0.1 (1.2), p=0.00005, and enhancements in β-cell function HOMA2-B; +21.6 (47.7); p<0.0001, along with better CGM metrics. These findings suggest that DT intervention could play a vital role in the future of T2D care.
Shamanna et al. (Wed,) studied this question.